Director, Strategic Engagement, Rheumatology

Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton’s Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized inflammation and disease progression in Multiple Sclerosis (MS). Zenas’ earlier stage programs include ZB021, a clinical-stage, potentially best-in-class, oral, IL-17AA/AF inhibitor; ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor; and ZB014, a preclinical half-life extended anti-CD-19 and FcγRIIb monoclonal antibody. We are seeking top talent who share our commitment to patients and have a track record of success in acquiring, developing and commercializing products across the globe. Our colleagues have an opportunity to engage in a fast-paced learning environment and experience individual and organizational success as we work towards becoming a global immunology and autoimmune disease leader, while living our values of Transparency, Relationships, Urgency, Excellence and Innovation – TRUE Innovation ! Position Summary: Zenas is seeking a passionate and talented individual for the role of Strategic Engagement Director (SED), Rheumatology. The SED is a field-based role that will be responsible for building and nurturing strategy with US KOLs. This role will be critical in helping us understand the dynamics of the Rheumatology community, obtaining insights that help advance educational offerings by Zenas, and will ultimately help build advocacy among the treater community – as well as galvanizing focus and collaboration internally on KOL engagement. It is an outstanding opportunity to make a significant impact for HCPs and the company. This position will report to the Senior Director, Strategic Engagement. Key Responsibilities: Create and manage US Commercial engagement plans for leading US KOLs, inclusive of establishing commercial engagement objectives and measurement against goals. Establish and nurture relationships with US KOLs nationally. Support KOL engagements with the US Commercial Team, Senior Leadership and Executive Committee throughout the year and at congresses Partner closely with KOLs and treating physicians to identify and refine peer-to-peer program offerings to ensure they are resonant with key customers Once a product is approved, maintain the promotional speaker bureau – identify and recruit potential speakers, train speakers on approved promotional slide decks, partner with HCP marketing team on planning the annual speaker training event, and assist speakers with completion of annual compliance training Partner with HCP marketing team on the execution of commercial HCP advisory boards: help identify appropriate advisors based on objectives and agenda and provide input into meeting objectives and content Partner with HCP marketing team on content development for peer to peer engagements by providing input on speaker programs, and cong